Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Anocca and Shinobi Partner to Develop TCR-T Cell Therapies for Oncology
Details : The partnership aims to use Shinobi’s iPS-T cell platform with novel TCRs, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies for solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : NJA-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $51.0 million
Deal Type : Series A Financing
Details : Shinobi will use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program, NJA-001, to treat GPC3+ solid tumor cancers toward the clinic.
Product Name : NJA-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : NJA-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $51.0 million
Deal Type : Series A Financing
Reset All
